Seelos therapeutics provides second quarter 2023 clinical update

- seelos expects to release top-line data in its registration directed study of sls-002 (intranasal racemic ketamine) for acute suicidal ideation and behavior (asib) in adults with major depressive disorder (mdd) in the third quarter of 2023. - seelos expects to release top-line data from its registrational phase ii/iii trial of sls-005 in amyotrophic lateral sclerosis (als) as part of the healey als platform in the fourth quarter of 2023.
SEEL Ratings Summary
SEEL Quant Ranking